Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 2/20 | 0.39 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.39 |
| ▸ | LYN | P07948 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 2/20 | 0.32 |
| ▸ | OXTR | P30559 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | ATP4A | P20648 | 1/20 | 0.32 |
| ▸ | ATP4B | P51164 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6915242 | 0.80 | MRGPRX4 (0.38) | PDE1APDE1BPDE1CHTR2AHTR2C | |
| SCHEMBL20142975 | 0.80 | MAPT (0.39) | PDE1APDE1BPDE1CKDM4EMEN1 | |
| SCHEMBL20138803 | 0.79 | SCN4A (0.38) | HTR2AHTR2CMEN1ALDH1A1KMT2A | |
| SCHEMBL6913736 | 0.78 | PDE1A (0.37) | PDE1APDE1BPDE1CLYNBTK | |
| SCHEMBL20138666 | 0.77 | TRPA1 (0.35) | PDE1APDE1BPDE1CSLC6A4HTR2A | |
| SCHEMBL20138672 | 0.77 | PSEN1 (0.37) | SLC6A4KDM4EALDH1A1HPGD | |
| SCHEMBL20138683 | 0.76 | — | — | |
| SCHEMBL20138658 | 0.75 | HTR1A (0.32) | PDE1APDE1BPDE1CHTR2AKDM4E | |
| SCHEMBL20138712 | 0.75 | HTR1A (0.36) | PDE1APDE1BPDE1CMAPK14HTR2A | |
| SCHEMBL6914242 | 0.74 | HTT (0.39) | PDE1APDE1BPDE1CSLC6A4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079886-B2 | Substituted triazole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9079886-B2 | Substituted triazole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2015-07-14 | — | — | US | disclosed |
| EP-2523949-B1 | NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICALS INC (US) | 2014-08-20 | — | — | EP | disclosed |
| US-20120295891-A1 | NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-11-22 | — | — | US | disclosed |
| US-20120295891-A1 | NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-11-22 | — | — | US | disclosed |
| WO-2011086099-A1 | NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295891-A1 | NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, APH1A | PDE1A 1077/4885PDE1B 1156/4885PDE1C 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.